RAMM PharmaXCNQ:RAMM Pretax Margin % is -356.34% as of Jan. 2026. The stock has 4 warning signs investors should review. Among 954 Drug Manufacturers companies, RAMM Pharma ranks worse than 94.44% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. RAMM Pharma's Pre-Tax Income for the
three
months ended in Jan. 2026 was C$-0.76 Mil. RAMM Pharma's Revenue for the
three
months ended in Jan. 2026 was C$0.21 Mil. Therefore, RAMM Pharma's pretax margin for the quarter that ended in Jan. 2026 was -356.34%.
The historical rank and industry rank for RAMM Pharma's Pretax Margin % or its related term are showing as below:
XCNQ:RAMM'
s Pretax Margin % Range Over the Past 10 Years
Min: -537.64 Med: -162.38 Max: -8.14
Current: -333.15
XCNQ:RAMM's Pretax Margin % is ranked worse than 94.44% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs XCNQ:RAMM: -333.15
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
RAMM Pharma Pretax Margin % Related Terms
RAMM Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for RAMM Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XCNQ:RAMM vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, RAMM Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RAMM Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RAMM Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where RAMM Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAMM Pharma (XCNQ:RAMM) has a Pretax Margin % of -356.34% as of Jan. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on RAMM Pharma and its competitors. According to the industry distribution chart, RAMM Pharma ranks #901 out of 954 companies in the Drug Manufacturers industry, placing it in the top 94.4%.
Is RAMM Pharma's Pretax Margin % too high?
RAMM Pharma's current Pretax Margin % is -356.34%. Based on the distribution chart, RAMM Pharma ranks #901 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does RAMM Pharma's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RAMM Pharma ranks #901 out of 954 companies for Pretax Margin %. This places RAMM Pharma in the lower half of its industry. The industry median Pretax Margin % is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on RAMM Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RAMM Pharma's current Pretax Margin % is -356.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current Pretax Margin % is -356.34%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current Pretax Margin % is -356.34% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:RAMM has been successfully added to your 